Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorinostat Plus Rituximab in Indolent Non-Hodgkin's Lymphoma
NCT00720876Phase 2Completed
- Sponsor
- City of Hope
- Start
- Jul 2008
- Primary completion
- Jun 2017
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vorinostat in Indolent Non-Hodgkin Lymphoma (INHL), sponsored by City of Hope. Started Jul 2008; status: completed.
02
Drugs
vorinostat
03
Conditions
Indolent Non-Hodgkin Lymphoma (INHL)
Beyond the preview
Go deeper on NCT00720876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00720876.